VINC vs. RDHL, CNSP, QLGN, AWH, THAR, ENSC, GLMD, PTPI, SCNI, and CERO
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include RedHill Biopharma (RDHL), CNS Pharmaceuticals (CNSP), Qualigen Therapeutics (QLGN), Aspira Women's Health (AWH), Tharimmune (THAR), Ensysce Biosciences (ENSC), Galmed Pharmaceuticals (GLMD), Petros Pharmaceuticals (PTPI), Scinai Immunotherapeutics (SCNI), and CERo Therapeutics (CERO). These companies are all part of the "pharmaceutical products" industry.
Vincerx Pharma vs.
Vincerx Pharma (NASDAQ:VINC) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.
RedHill Biopharma received 406 more outperform votes than Vincerx Pharma when rated by MarketBeat users. Likewise, 66.00% of users gave RedHill Biopharma an outperform vote while only 65.63% of users gave Vincerx Pharma an outperform vote.
RedHill Biopharma has higher revenue and earnings than Vincerx Pharma.
Vincerx Pharma currently has a consensus price target of $40.00, suggesting a potential upside of 39,900.00%. Given Vincerx Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Vincerx Pharma is more favorable than RedHill Biopharma.
In the previous week, RedHill Biopharma had 2 more articles in the media than Vincerx Pharma. MarketBeat recorded 5 mentions for RedHill Biopharma and 3 mentions for Vincerx Pharma. RedHill Biopharma's average media sentiment score of 0.14 beat Vincerx Pharma's score of -0.25 indicating that RedHill Biopharma is being referred to more favorably in the news media.
Vincerx Pharma has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 4.44, suggesting that its share price is 344% more volatile than the S&P 500.
RedHill Biopharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.
44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 7.2% of RedHill Biopharma shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 6.8% of RedHill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
RedHill Biopharma beats Vincerx Pharma on 9 of the 14 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:VINC) was last updated on 4/22/2025 by MarketBeat.com Staff
